TE

Sihuan Pharmaceutical Holdings Group LtdMUN Sihuan Pharmaceutical Stock Report

Last reporting period 31 Dec, 2023

Updated 11 Nov, 2024

Last price

Market cap $B

0.208

Micro

Exchange

XMUN - Boerse Muenchen

TEL1.MU Stock Analysis

TE

Uncovered

Sihuan Pharmaceutical Holdings Group Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

13/100

Low score

Market cap $B

0.208

Dividend yield

3.23 %

Shares outstanding

9 330 B

Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 3,896 full-time employees. The company went IPO on 2010-10-28. The firm is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.

View Section: Eyestock Rating